by Brenda Baletti, Ph.D., Childrens Health Defense:
An investigation by Gilead, maker of remdesivir, confirmed the presence of glass, according to the company recall notice posted on the FDA website warning the contaminated vials can cause stroke and “even lead to death.”
Pharmaceutical giant Gilead recalled one batch of its COVID-19 antiviral drug Veklury, the brand name for remdesivir, after glass particles were discovered in vials of the drug, Newsweek reported.
TRUTH LIVES on at https://sgtreport.tv/
A company investigation, prompted by a customer complaint, confirmed the presence of glass, according to the company recall notice posted on the U.S. Food and Drug Administration (FDA) website.
Gilead distributed the batch, identified as Veklury lot No. 47035CFA across the U.S. beginning on July 16. The batch isn’t set to expire until November 2025.
If a product containing glass is injected, it may result in localized swelling or, “the glass particulate can potentially travel, through the blood vessels, to various organs and block blood vessels in the heart, lungs or brain which can cause stroke and even lead to death,” the company warned in the recall notice.
Gilead said it is informing distributors and customers via a letter sent to UPS Next Day Air. The letter advises facilities that have the recalled drug to stop using it and return the vials to the company following the instructions in the letter.
Gilead said it has not received any reports of adverse events related to this lot.
The company didn’t say where the lots were manufactured or by whom and did not respond to The Defender’s request for comment on those questions.
Read More @ ChildrensHealthDefense.org
